Anti-VEGF Monoclonal Antibody

Phase 2

Anti-VEGF Monoclonal Antibody is one of 6 therapeutic programs targeting Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaNot yet recruiting

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

1 2

TRODELVY

Gilead

Phase 2

1 3

Avastin

BBio-Thera Solutions

Phase 2

1 4

Paraplatin

AAvyxa

Phase 2

1 5

Pegylated Liposomal Doxorubicin Hydrochloride

NNational Cancer Institute (NCI)

Phase 2

1 6

Anti-VEGF Monoclonal Antibody

NNational Cancer Institute (NCI)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Not yet recruiting

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07504588

Clinical

Trials by Indication[1]

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma1 trial

A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07504588·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-VEGF Monoclonal Antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Anti-VEGF Monoclonal Antibody. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Anti-VEGF Monoclonal Antibody

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News